News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
167,817 Results
Type
Article (6334)
Company Profile (22)
Press Release (161461)
Section
Business (44153)
Career Advice (74)
Deals (8044)
Drug Delivery (12)
Drug Development (27112)
Employer Resources (7)
FDA (4940)
Job Trends (3921)
News (84948)
Policy (8729)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (1)
Academia (600)
Accelerated approval (1)
Allergies (21)
Alliances (11490)
ALS (31)
Alzheimer's disease (346)
Antibody-drug conjugate (ADC) (26)
Approvals (4996)
Artificial intelligence (101)
Autoimmune disease (9)
Automation (7)
Bankruptcy (60)
Best Places to Work (3621)
Biosimilars (31)
Biotechnology (21)
Bladder cancer (38)
Brain cancer (9)
Breast cancer (129)
Cancer (937)
Cardiovascular disease (64)
Career advice (70)
Career pathing (2)
CAR-T (31)
Cell therapy (115)
Cervical cancer (11)
Clinical research (22658)
Collaboration (335)
Compensation (195)
Complete response letters (4)
COVID-19 (1843)
CRISPR (12)
C-suite (75)
Cystic fibrosis (25)
Data (1010)
Depression (17)
Diabetes (71)
Diagnostics (1987)
Digital health (8)
Diversity (1)
Diversity, equity & inclusion (1)
Drug discovery (32)
Drug pricing (12)
Drug shortages (2)
Duchenne muscular dystrophy (21)
Earnings (20888)
Editorial (3)
Employer resources (5)
Events (26099)
Executive appointments (297)
FDA (5463)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (289)
Gene editing (25)
Generative AI (4)
Gene therapy (94)
GLP-1 (128)
Government (1296)
Grass and pollen (2)
Guidances (17)
Healthcare (4461)
Huntington's disease (6)
IgA nephropathy (4)
Immunology and inflammation (22)
Indications (12)
Infectious disease (1915)
Inflammatory bowel disease (34)
Inflation Reduction Act (1)
Influenza (38)
Intellectual property (32)
Interviews (7)
IPO (3620)
IRA (4)
Job creations (601)
Job search strategy (66)
Kidney cancer (6)
Labor market (3)
Layoffs (61)
Legal (1781)
Liver cancer (20)
Lung cancer (147)
Lymphoma (70)
Machine learning (1)
Management (2)
Manufacturing (85)
MASH (25)
Medical device (2866)
Medtech (2866)
Mergers & acquisitions (4676)
Metabolic disorders (154)
Multiple sclerosis (21)
NASH (5)
Neurodegenerative disease (21)
Neuropsychiatric disorders (4)
Neuroscience (502)
NextGen: Class of 2025 (768)
Non-profit (819)
Northern California (882)
Now hiring (2)
Obesity (53)
Opinion (25)
Ovarian cancer (30)
Pain (32)
Pancreatic cancer (32)
Parkinson's disease (42)
Partnered (4)
Patents (69)
Patient recruitment (36)
Peanut (12)
People (11512)
Pharmaceutical (3)
Phase I (6265)
Phase II (9606)
Phase III (8679)
Pipeline (416)
Podcasts (3)
Policy (8)
Postmarket research (992)
Preclinical (2318)
Press Release (55)
Prostate cancer (47)
Psychedelics (4)
Radiopharmaceuticals (69)
Rare diseases (99)
Real estate (1169)
Recruiting (3)
Regulatory (6379)
Reports (10)
Research institute (702)
Resumes & cover letters (7)
Rett syndrome (4)
RNA editing (1)
RSV (14)
Schizophrenia (21)
Series A (51)
Series B (34)
Service/supplier (3)
Sickle cell disease (19)
Southern California (688)
Special edition (1)
Spinal muscular atrophy (60)
Sponsored (3)
Startups (511)
State (1)
Stomach cancer (1)
Supply chain (25)
Tariffs (1)
The Weekly (3)
United States (9094)
Vaccines (337)
Venture capitalists (1)
Webinars (1)
Weight loss (13)
Women's health (10)
Worklife (1)
Date
Today (51)
Last 7 days (331)
Last 30 days (1271)
Last 365 days (12742)
2025 (3984)
2024 (11241)
2023 (10673)
2022 (14730)
2021 (16011)
2020 (15815)
2019 (10068)
2018 (7427)
2017 (7468)
2016 (7017)
2015 (8446)
2014 (6096)
2013 (5043)
2012 (5698)
2011 (5844)
2010 (5822)
Location
Africa (105)
Alabama (14)
Arizona (24)
Arkansas (3)
Asia (8139)
Australia (951)
California (2009)
Canada (661)
China (145)
Colorado (116)
Connecticut (138)
Delaware (90)
Europe (20438)
Florida (241)
Georgia (62)
Idaho (7)
Illinois (161)
India (11)
Indiana (64)
Iowa (4)
Japan (81)
Kansas (9)
Kentucky (4)
Louisiana (1)
Maine (4)
Maryland (207)
Massachusetts (1647)
Michigan (34)
Minnesota (78)
Missouri (28)
Montana (2)
Nebraska (2)
Nevada (24)
New Hampshire (68)
New Jersey (1514)
New Mexico (22)
New York (787)
North Carolina (912)
North Dakota (8)
Northern California (882)
Ohio (47)
Oklahoma (3)
Oregon (13)
Pennsylvania (335)
Puerto Rico (2)
Rhode Island (8)
South America (236)
South Carolina (2)
South Dakota (1)
Southern California (688)
Tennessee (40)
Texas (325)
Utah (28)
Virginia (49)
Washington D.C. (14)
Washington State (184)
West Virginia (2)
Wisconsin (39)
167,817 Results for "janssen pharmaceutica n v".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), and Janssen PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (“Janssen PMP”) are pleased to announce a significant expansion to their existing Exclusive Evaluation and Option Agreement
September 6, 2023
·
9 min read
Business
Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration
Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the “Second Interim Award”) from the arbitral tribunal (the “Tribunal”) in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V.
April 25, 2023
·
4 min read
MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”), and JANSSEN PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson
May 23, 2023
·
7 min read
Business
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
January 8, 2024
·
2 min read
Press Releases
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
January 15, 2025
·
1 min read
Press Releases
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers
February 19, 2025
·
8 min read
Press Releases
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
January 27, 2025
·
3 min read
Press Releases
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025
February 11, 2025
·
4 min read
Policy
Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. (“Janssen”), a subsidiary of Johnson & Johnson.
April 19, 2022
·
4 min read
QIAGEN N.V. to release results for Q1 2024 and hold webcast
QIAGEN N.V. announced plans to release results for the first quarter 2024.
April 9, 2024
·
1 min read
1 of 16,782
Next
